Fortrea Holdings (FTRE) Operating Income: History & Chart

Fortrea Holdings Inc.(FTRE)

Biotechnology · Durham, NC

$20.00+0.60 (+3.09%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Fortrea Holdings Inc.

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

Durham, NC

14,000 employees

www.fortrea.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Anshul Thakral

View full financials

Operating Income

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly operating income is $14.80M with QoQ Growth of +348.48%. Operating income measures profit from core operations before interest and taxes.

Operating Income

FTRE Operating Income

$14.80M

Reported quarterly operating income; no daily interpolation. Q2 FY2026 (2026-06-30): $14.80M.

-65.01% over 10Y

FTRE Quarterly Operating Income Growth (YoY)

Operating Income growth vs the same fiscal quarter in the prior fiscal year, last 8 comparable quarters.

FTRE EV/EBIT

Full EV/EBIT page

EV/EBIT

FTRE EV/EBIT Chart

259.17x

Current FMP quote-based enterprise value / four-quarter operating income Quote observation: 2026-10-03T00:15:29.228Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.

Quarterly Operating Income History

Period	Operating Income	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$14.80M	+348.48%	N/A
Q1 FY2026Period end 2026-03-31	$3.30M	(62.50%)	N/A
Q4 FY2025Period end 2025-12-31	$8.80M	N/A	N/A
Q3 FY2025Period end 2025-09-30	($15.90M)	(45.87%)	+11.67%
Q2 FY2025Period end 2025-06-30	($10.90M)	+97.90%	+78.59%
Q1 FY2025Period end 2025-03-31	($520.10M)	(835.43%)	(1290.64%)
Q4 FY2024Period end 2024-12-31	($55.60M)	(208.89%)	(419.63%)
Q3 FY2024Period end 2024-09-30	($18.00M)	+64.64%	N/A
Q2 FY2024Period end 2024-06-30	($50.90M)	(36.10%)	N/A
Q1 FY2024Period end 2024-03-31	($37.40M)	(249.53%)	N/A
Q4 FY2023Period end 2023-12-31	($10.70M)	N/A	(28.92%)
Q3 FY2023Period end 2023-09-30	$10.30M	(67.41%)	(85.05%)
Q2 FY2023Period end 2023-06-30	$31.60M	+124.11%	(62.47%)
Q1 FY2023Period end 2023-03-31	$14.10M	N/A	(66.67%)
Q4 FY2022Period end 2022-12-31	($8.30M)	N/A	N/A
Q3 FY2022Period end 2022-09-30	$68.90M	(18.17%)	N/A
Q2 FY2022Period end 2022-06-30	$84.20M	+99.05%	N/A
Q1 FY2022Period end 2022-03-31	$42.30M	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.